Alpine Global Management’s MacroGenics MGNX Stock Holding History

Alpine Global Management’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,142	Closed	-$12.9K	–	191
2025 Q1	$12.9K	Buy	+10,142	New	+$26.5K	﹤0.01%	124
2023 Q1	–	Sell	-14,248	Closed	-$96K	–	312
2022 Q4	$96K	Buy	+14,248	New	+$78.1K	0.03%	271
2020 Q1	–	Sell	-12,379	Closed	-$135K	–	361
2019 Q4	$135K	Buy	+12,379	New	+$123K	0.03%	346

Other funds holding MGNX

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alpine Global Management's MGNX Position: Q2 2025 in Review

Alpine Global Management sold out of MacroGenics (MGNX) in Q2 2025, closing a stake of 10,142 shares — an estimated $12.9K sold.

Alpine Global Management first reported a position in MGNX in Q4 2019 and held it in 3 quarters. The position peaked at $135K in Q4 2019. 112 funds tracked by Wall St. Rank hold MGNX as of Q2 2025.

Alpine Global Management reported no remaining MacroGenics position as of Q2 2025 after selling out during the quarter.
Alpine Global Management sold 10,142 MacroGenics shares in Q2 2025, an estimated $12.9K.
Alpine Global Management first reported a position in MacroGenics in Q4 2019 and held it in 3 quarters.
Alpine Global Management's MacroGenics position peaked at $135K in Q4 2019.
112 funds tracked by Wall St. Rank held MacroGenics as of Q2 2025.

Based on Alpine Global Management's 13F filing for Q2 2025, filed 14 Aug 2025.